TG Therapeutics jumps as Q1 revenue hits ~$205M and 2026 guidance rises
TG Therapeutics shares rose after the company reported Q1 2026 total global revenue of about $205 million and BRIUMVI U.S. net revenue of about $195 million. Management raised full-year 2026 total global revenue guidance to about $925 million and lifted BRIUMVI U.S. guidance to $885–900 million.
1. What’s driving TGTX today
TG Therapeutics (TGTX) is moving higher after posting first-quarter 2026 results and increasing its 2026 outlook. The company reported total global revenue of about $205 million, driven primarily by BRIUMVI, including approximately $194.8 million of BRIUMVI U.S. net product revenue, and said it delivered net income of $19.8 million for the quarter. (stocktitan.net)
2. Guidance raise is the key catalyst
The main headline is the raised 2026 forecast: TG increased full-year 2026 total global revenue guidance to about $925 million and lifted BRIUMVI U.S. net product revenue guidance to $885–900 million. The guidance increase follows what the company described as stronger-than-expected demand and record new patient starts for BRIUMVI. (stocktitan.net)
3. What investors will watch next
With the stock reacting to the guide-up, attention now shifts to whether prescription momentum can hold through the rest of 2026 and how margins and spending trend as commercialization scales. Investors are also likely to monitor upcoming clinical and lifecycle-expansion readouts referenced by the company, including topline ENHANCE Phase 3 data expected mid-2026 and topline subcutaneous BRIUMVI data expected by year-end 2026/early 2027. (stocktitan.net)